U.S. Stocks Open Lower on Tuesday; Genprex Surges Another 125% After Soaring 266% Yesterday

Tiger Newspress10-22

US stocks fell for a second day Tuesday as a back-up in interest rates overshadowed a solid start to earnings reporting season.

Gene therapy company Genprex surged another 125% in morning trading on Tuesday after soaring 266% on Monday. Genprex’s gene therapy trial progress are driving strong interest.

Last week, US-based Genprex has received approval from the Safety Review Committee (SRC) to proceed to the highest dose group of 0.12mg/kg in the Phase I portion of the Acclaim-3 trial of Reqorsa Gene Therapy (quaratusugene ozeplasmid) for extensive stage small cell lung cancer (ES-SCLC).

The trial is designed to evaluate the gene therapy, along with Genentech’s Tecentriq (atezolizumab) as maintenance therapy, for ES-SCLC patients.

This latest move comes after the company completed the 0.09mg/kg dose group.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1189704806?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-22 21:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1189704806","market":"us","top_or_hot":-1,"title":"U.S. Stocks Open Lower on Tuesday; Genprex Surges Another 125% After Soaring 266% Yesterday","media":"Tiger Newspress","content":"<html><head></head><body><p>US stocks fell for a second day Tuesday as a back-up in interest rates overshadowed a solid start to earnings reporting season.</p><p>Gene therapy company Genprex surged another 125% in morning trading on Tuesday after soaring 266% on Monday. Genprex’s gene therapy trial progress are driving strong interest.</p><p>Last week, US-based Genprex has received approval from the Safety Review Committee (SRC) to proceed to the highest dose group of 0.12mg/kg in the Phase I portion of the Acclaim-3 trial of Reqorsa Gene Therapy (quaratusugene ozeplasmid) for extensive stage small cell lung cancer (ES-SCLC).</p><p style=\"text-align: start;\">The trial is designed to evaluate the gene therapy, along with Genentech’s Tecentriq (atezolizumab) as maintenance therapy, for ES-SCLC patients.</p><p style=\"text-align: start;\">This latest move comes after the company completed the 0.09mg/kg dose group.</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>U.S. Stocks Open Lower on Tuesday; Genprex Surges Another 125% After Soaring 266% Yesterday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nU.S. Stocks Open Lower on Tuesday; Genprex Surges Another 125% After Soaring 266% Yesterday\n</h2>\n\n<h4 class=\"meta\">\n\n2024-10-22 21:30 北京时间&nbsp;&nbsp;&nbsp;<strong>Tiger Newspress</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>US stocks fell for a second day Tuesday as a back-up in interest rates overshadowed a solid start to earnings reporting season.Gene therapy company Genprex surged another 125% in morning trading on ...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":".IXIC","symbol_name":"NASDAQ Composite","start_time":0,"source_url":"","article_id":"1189704806","we_media_id":"1079075236","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1189704806","pubTimestamp":1729603800,"sourceInfo":null,"weMediaInfo":{"media_name":"Tiger Newspress","introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"summary":"U.S. Stocks Open Lower on Tuesday; Genprex Surges Another 125% After Soaring 266% Yesterday","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{".IXIC":"NASDAQ Composite",".DJI":"道琼斯",".SPX":"S&P 500 Index","GNPX":"Genprex, Inc."},"translate_title":"美股周二低开；Genprex继昨日飙升266%后再飙升125%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{".DJI":1.1,".IXIC":1.1,".SPX":1.1,"GNPX":1.1},"content_text":"US stocks fell for a second day Tuesday as a back-up in interest rates overshadowed a solid start to earnings reporting season.Gene therapy company Genprex surged another 125% in morning trading on Tuesday after soaring 266% on Monday. Genprex’s gene therapy trial progress are driving strong interest.Last week, US-based Genprex has received approval from the Safety Review Committee (SRC) to proceed to the highest dose group of 0.12mg/kg in the Phase I portion of the Acclaim-3 trial of Reqorsa Gene Therapy (quaratusugene ozeplasmid) for extensive stage small cell lung cancer (ES-SCLC).The trial is designed to evaluate the gene therapy, along with Genentech’s Tecentriq (atezolizumab) as maintenance therapy, for ES-SCLC patients.This latest move comes after the company completed the 0.09mg/kg dose group.","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":5,"commentSize":0,"repostSize":0,"favoriteSize":1,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1189704806"}